Dexamethasone Intravitreal Implant (Ozurdex®)

Assessment Status NCPE Assessment Process Complete
Drug Dexamethasone Intravitreal Implant
Brand Ozurdex®
Indication Treatment of macular oedema following Retinal Vein Occlusion
Assessment Process
Rapid review commissioned 12/11/2010
Rapid review completed 16/12/2010
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full pharmacoeconomic assessment commissioned by HSE 24/11/2011
NCPE assessment completed 16/03/2012
NCPE assessment outcome Reimbursement not recommended the submitted price, Ozurdex® cannot be considered cost-effective therapy for the treatment of macular oedema following retinal vein occlusion

Technical Summary

July 2013

Following resubmission of pricing information the NCPE conclude that Ozurdex® is a cost effective treatment strategy versus observation (base case) in RVO. The ICER for Ozurdex® versus observation is €25,601/QALY (basecase).   The probability of cost effectiveness at a threshold of €45,000/QALY is 88.97%.